Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics Applies to FDA for Orphan Drug Designation for Treatment of Autoimmune Hepatitis

MarketWire Canada September 27, 2017

Revive Therapeutics and South Carolina Research Foundation Enter into Exclusive License Agreement for Cannabinoids-Based Therapeutics in the Treatment of Liver Diseases

Marketwired September 19, 2017

Revive Therapeutics Advances Research Program of Cannabinoid-Based Drug Delivery Technology for the Medical Marijuana and Pharmaceutical Markets

Marketwired September 12, 2017

Revive Therapeutics Appoints Dr. Arun Sanyal, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases

Marketwired August 22, 2017

Revive Therapeutics Appoints Dr. Ram Subramanian, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases

MarketWire Canada August 15, 2017

Revive Therapeutics Announces Positive Results from its Research Program of Cannabinoid-Based Therapies Targeting Liver Diseases

Marketwired June 7, 2017

Revive Therapeutics Announces Sponsored Research Agreement with the University of Wisconsin-Madison to Evaluate a Novel Drug Delivery Technology Focused on Cannabinoids

Marketwired May 30, 2017

Revive Therapeutics Ltd. Announces Results for the Three and Nine Months Ended March 31, 2017

Marketwired May 25, 2017

Revive Therapeutics Ltd. Grants Incentive Stock Options

Marketwired April 12, 2017

Revive Therapeutics Provides Corporate Update

Marketwired March 29, 2017

Revive Therapeutics Appoints Dr. Scott Friedman, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases

Marketwired March 22, 2017

Revive Therapeutics Appoints Dr. Yanlin Wang, MD, PhD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Kidney Diseases

MarketWire Canada March 8, 2017

Revive Therapeutics Announces Initiation of Research Discovery Program of Cannabinoid-Based Therapies Targeting Liver Diseases

MarketWire Canada March 1, 2017

Revive Therapeutics Ltd. Announces Results for the Three and Six Months Ended December 31, 2016

MarketWire Canada February 28, 2017

Revive Therapeutics Announces Term Sheet with InMed Pharmaceuticals for the Discovery and Development of Cannabinoid-Based Therapy Targeting Kidney Diseases

MarketWire Canada February 22, 2017

Revive Therapeutics Announces Expansion into Cannabinoid-Based Therapies Targeting Liver Diseases

MarketWire Canada February 16, 2017

Revive Therapeutics Announces Initiation of a Phase 2 Study of REV-004 (Bucillamine) in Cystinuria

MarketWire Canada February 7, 2017

Revive Therapeutics Appoints Dr. Pritesh Kumar as Scientific Advisor for Cannabinoid-Based Therapeutics

MarketWire Canada January 24, 2017

Revive Therapeutics Engages Massachusetts General Hospital for Cystinuria Phase 2 Study

MarketWire Canada January 12, 2017

Revive Therapeutics Engages NYU School of Medicine for Cystinuria Phase 2 Study

MarketWire Canada December 21, 2016